Pharmaceutical

Nuntius partners with Taiho to develop mRNA cancer therapies

UK-based biotechnology company Nuntius Therapeutics has announced a strategic collaboration agreement with Japan’s Taiho Pharmaceutical to develop next-generation messenger ribonucleic acid (mRNA) cancer immunotherapies.

Aug 17, 2024 - 04:00
Nuntius partners with Taiho to develop mRNA cancer therapies
UK-based biotechnology company Nuntius Therapeutics has announced a strategic collaboration agreement with Japan’s Taiho Pharmaceutical to develop next-generation messenger ribonucleic acid (mRNA) cancer immunotherapies.
Read the original article

Tags:

Previous Article

The Genomic Medicine Revolution: Multi-Modality Approaches in Advanced Therapies 

Next Article

AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

With affirmative action off the table, medical schools plan new diversity tactics

With affirmative action off the table, medical schools ...

Sep 6, 2023

Astellas seeks approval for Padcev-Keytruda combo therapy in Japan

Astellas seeks approval for Padcev-Keytruda combo thera...

Jan 31, 2024

A ‘sense of urgency’ swirls in the UK pharma regulatory landscape

A ‘sense of urgency’ swirls in the UK pharma regulatory...

Jan 23, 2024